Sift Biosciences
Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases
$3.7MPre-Seed
Role not disclosedSU
SBI US Gateway Fund
Activity from announced rounds
Activity in this selectionAI
SBI US Gateway Fund is the specified investment vehicle named by Sift and Typewriter.
Recorded funding activity
Sift develops peptide immunotherapies using AI and profiling. Typewriter develops RNA-based insertion of therapeutic genes. These financing relationships belong to the named vehicle rather than to every SBI group entity.
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $3.7M 1 disclosed · full round size, not this investor’s share